| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8340180 | Methods | 2017 | 6 Pages |
Abstract
Considering the wide diffusion of PCa in the Europe and the United States, the presence of these new diagnostic techniques able to detect the disease with high sensitivity and specificity might have a clinical impact on the management of patients. PET/CT imaging with new radiopharmaceuticals can implement the patient management identifying lesion(s) not detectable with conventional imaging procedures. In this review article will be discussed the most promising new PET radiopharmaceuticals (68Â Ga-PSMA-11, 18Â F-FACBC, 68Â Ga-RM2) available at the moment, focusing the attention on their accuracy and their impact on treatment strategy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Francesco Ceci, Paolo Castellucci, Juliano J. Cerci, Stefano Fanti,